REMS Evaluations Not Perfect, FDA Questions Assessment Methods
The FDA is questioning surveys and other assessment methods drugmakers are using to evaluate whether risk evaluation and mitigation strategies (REMS) work. An initial review shows several shortcomings.
This article is viewable by subscribers only. To view this article, please select an option below.